CVE-2023-2491

Description

A flaw was found in the Emacs text editor. Processing a specially crafted org-mode code with the "org-babel-execute:latex" function in ob-latex.el can result in arbitrary command execution. This CVE exists because of a CVE-2023-28617 security regression for the emacs package in Red Hat Enterprise Linux 8.8 and Red Hat Enterprise Linux 9.2.

Category

7.8
CVSS
Severity: High
CVSS 3.1 •
EPSS 0.06%
Third-Party Advisory redhat.com Third-Party Advisory redhat.com Third-Party Advisory redhat.com Third-Party Advisory redhat.com
Affected: n/a emacs
Published at:
Updated at:

References

Link Tags
https://bugzilla.redhat.com/show_bug.cgi?id=2192873 third party advisory issue tracking
https://access.redhat.com/security/cve/CVE-2023-2491 third party advisory
https://access.redhat.com/errata/RHSA-2023:3104 third party advisory
https://access.redhat.com/errata/RHSA-2023:2626 third party advisory

Frequently Asked Questions

What is the severity of CVE-2023-2491?
CVE-2023-2491 has been scored as a high severity vulnerability.
How to fix CVE-2023-2491?
To fix CVE-2023-2491, make sure you are using an up-to-date version of the affected component(s) by checking the vendor release notes. As for now, there are no other specific guidelines available.
Is CVE-2023-2491 being actively exploited in the wild?
As for now, there are no information to confirm that CVE-2023-2491 is being actively exploited. According to its EPSS score, there is a ~0% probability that this vulnerability will be exploited by malicious actors in the next 30 days.
What software or system is affected by CVE-2023-2491?
CVE-2023-2491 affects n/a emacs.
This platform uses data from the NIST NVD, MITRE CVE, MITRE CWE, First.org and CISA KEV but is not endorsed or certified by these entities. CVE is a registred trademark of the MITRE Corporation and the authoritative source of CVE content is MITRE's CVE web site. CWE is a registred trademark of the MITRE Corporation and the authoritative source of CWE content is MITRE's CWE web site.
© 2025 Under My Watch. All Rights Reserved.